New data presented at SABCS 2025 reinforced the role of platinum-based therapy in early-stage triple-negative breast cancer, showing improved pathologic complete response rates in both BRCA-mutant and BRCA–wild-type disease. The discussion also highlights how neoadjuvant therapy helps identify residual disease and guide adjuvant treatment decisions, particularly as ADC trials expand options for patients with residual disease. Drs. Reshma Mahtani, Heather McArthur, and Anne O’Dea review how these findings align with current KEYNOTE-522–based treatment approaches and evolving clinical practice. Sponsored By Gilead.